RE:RE:RE:RE:Dream.Gbathat wrote: I also have wondered the same and posted that here previously. It is unclear to me. All I know from the PRs is that PMN 310 appears to be tied to aducanumab's progression. I also see that PMN310 has been acknowledged as next-gen in a review paper published by others in the industry. I am trying to connect the dots, just like the rest of us on this board.
It's not PMN310 that's attached to aducanumabs progression ...it's the amyloid science pertaining to alzhiemers...there has been constant failures and setbacks for the amyloid approach and many dont want to flog a dead horse....that's what everyone is waiting to see ....the FDA endorsement is apparently the best validation that can happen at this time...and get investors t.hat were reluctant to put money out and even more important...encourage other researchers to pursue this direction and create a better drug than what Biogen has....